Immunomodulatory effects of L-carnitine and q10 in mouse spleen exposed to low-frequency high-intensity magnetic field.
In the current study, we have investigated the bioeffects of repeated exposure to low-frequency (50 Hz) high-intensity (20 mT; 200 G) electromagnetic field (EMF) on some immune parameters in mice. The animals were exposed to EMF daily for 30 min three times per week for 2 weeks. We also studied the possible immunomodulatory effects of two anti-radical substances known to have non-specific immunostimulant effects namely, L-carnitine (200 mg/kg body weight i.p.) and Q10 (200 mg/kg body weight, p.o.). Both drugs were given 1 h prior to each EMF exposure. Immune endpoints included total body weight, spleen/body weight ratio, splenocytes viability, total and differential white blood cell (WBCs; lymphocytes, monocytes, neutrophils) counts, as well as the lymphocyte proliferation induced by the mitogens; phytohaemagglutinin (PHA), concanavalin-A (Con-A) and lipoploysaccharide (LPS). Magnetic field decreased splenocyte viability, WBCs count, as well as mitogens-induced lymphocyte proliferation. L-carnitine, but not Q10 could ameliorate the adverse effects of EMF on the vast majority of the immune parameters tested, suggesting a possible immunoprotective role of L-carnitine under the current experimental conditions.
Arafa
Hossam M M
HM
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt. arafageni@hotmail.com
Abd-Allah
Adel R A
AR
El-Mahdy
Mohamad A
MA
Ramadan
Laila A
LA
Hamada
Farid M A
FM
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001835:Body Weight / Q000528:radiation effects; D002331:Carnitine / Q000627:therapeutic use*; D002470:Cell Survival / Q000528:radiation effects; D003067:Coenzymes; D003208:Concanavalin A / Q000494:pharmacology; D004574:Electromagnetic Fields / Q000009:adverse effects*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D051379:Mice; D008934:Mitogens / Q000494:pharmacology; D009000:Monocytes / Q000473:pathology / Q000528:radiation effects; D009504:Neutrophils; D010835:Phytohemagglutinins / Q000494:pharmacology; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D013154:Spleen / Q000473:pathology* / Q000528:radiation effects; D013268:Stimulation, Chemical; D013997:Time Factors; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000975:Antioxidants; D003067:Coenzymes; D008070:Lipopolysaccharides; D008934:Mitogens; D010835:Phytohemagglutinins; D011837:Radiation-Protective Agents; D003208:Concanavalin A; D014451:Ubiquinone; C024989:coenzyme Q10; D002331:Carnitine